Lepirudin

BreastfeedingGeriatricPediatric
  • TRADE NAME: Refludan (ZLB Behring)
  • INDICATIONS: Anticoagulation in heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease
  • CLASS: Anticoagulant, Thrombin inhibitor
  • HALF-LIFE: 1.3 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Abciximab, Acenocoumarol, Clopidogrel, Eptifibatide, Streptokinase, Thrombolytics, Ticlopidine, Tirofiban, Vitamin K antagonists, Warfarin

PREGNANCY CATEGORY: B

Contra-indicated in patients with a generalized hemostatic abnormality such as
hemophilia, Christmas disease, idiopathic thrombocytopenic purpura and in patients with active bleeding from a local lesion such as acute ulcer or ulcerating carcinoma; in patients who have had recent cranial, spinal, eye or ear surgery or trauma; hypersensitivity to hirudins; shock.

Our database has 22 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
HEMATOLOGIC.
RESPIRATORY.
OTHER.


Page last updated 09/03/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top